Altace New Indications, Line Extensions Top King R&D Pipeline
Executive Summary
New indications for the ACE inhibitor Altace top the list of pipeline projects being developed by King to fuel future growth, the company said during an investor presentation April 12
You may also be interested in...
King Defense Against Generic ACE Inhibitors May Include Increased Spending
King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call
King Defense Against Generic ACE Inhibitors May Include Increased Spending
King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan